Does the media favor PLX or OLMA?

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Olema Pharmaceuticals and 2 mentions for Protalix BioTherapeutics. Olema Pharmaceuticals' average media sentiment score of 0.39 beat Protalix BioTherapeutics' score of 0.24 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PLX or CADL?

In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 2 mentions for Protalix BioTherapeutics and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.50 beat Protalix BioTherapeutics' score of 0.24 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GERN or PLX?

In the previous week, Geron had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Geron and 2 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.24 beat Geron's score of 0.13 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PLX or RIGL?

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 2 mentions for Protalix BioTherapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.42 beat Protalix BioTherapeutics' score of 0.24 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PLX or CLYM?

In the previous week, Climb Bio had 5 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for Climb Bio and 2 mentions for Protalix BioTherapeutics. Climb Bio's average media sentiment score of 0.68 beat Protalix BioTherapeutics' score of 0.24 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protalix BioTherapeutics (PLX) Competitors

$2.69 -0.01 (-0.37%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.67 -0.02 (-0.82%)

As of 09/18/2026 07:56 PM Eastern

Compare

PLX vs. OLMA, CADL, GERN, RIGL, and CLYM

Should you buy Protalix BioTherapeutics stock or one of its competitors? Protalix BioTherapeutics's main competitors and comparable companies include Olema Pharmaceuticals (OLMA), Candel Therapeutics (CADL), Geron (GERN), Rigel Pharmaceuticals (RIGL), and Climb Bio (CLYM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protalix BioTherapeutics compare to Olema Pharmaceuticals?

Protalix BioTherapeutics (NYSE:PLX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.69	$8.31M	$0.23	11.70
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Olema Pharmaceuticals and 2 mentions for Protalix BioTherapeutics. Olema Pharmaceuticals' average media sentiment score of 0.39 beat Protalix BioTherapeutics' score of 0.24 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics presently has a consensus target price of $12.00, indicating a potential upside of 346.10%. Olema Pharmaceuticals has a consensus target price of $40.60, indicating a potential upside of 313.44%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Olema Pharmaceuticals has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Summary

Olema Pharmaceuticals beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 2 mentions for Protalix BioTherapeutics and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.50 beat Protalix BioTherapeutics' score of 0.24 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 346.10%. Candel Therapeutics has a consensus price target of $19.29, suggesting a potential upside of 77.99%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Candel Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Candel Therapeutics	N/A	-76.98%	-48.50%

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.69	$8.31M	$0.23	11.70
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Protalix BioTherapeutics has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.48, meaning that its share price is 148% less volatile than the broader market.

Summary

Protalix BioTherapeutics beats Candel Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Geron?

Geron (NASDAQ:GERN) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

73.7% of Geron shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Protalix BioTherapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.54	-$83.50M	-$0.11	N/A
Protalix BioTherapeutics	$80.62M	2.69	$8.31M	$0.23	11.70

Geron currently has a consensus price target of $4.00, indicating a potential upside of 207.69%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 346.10%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Geron had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Geron and 2 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.24 beat Geron's score of 0.13 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics has a net margin of -21.03% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Summary

Geron beats Protalix BioTherapeutics on 9 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Protalix BioTherapeutics (NYSE:PLX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 2 mentions for Protalix BioTherapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.42 beat Protalix BioTherapeutics' score of 0.24 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Protalix BioTherapeutics' net margin of -21.03%. Rigel Pharmaceuticals' return on equity of 22.95% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Protalix BioTherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 346.10%. Rigel Pharmaceuticals has a consensus target price of $59.00, suggesting a potential upside of 26.50%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher revenue and earnings than Protalix BioTherapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.69	$8.31M	$0.23	11.70
Rigel Pharmaceuticals	$294.28M	2.93	$367.02M	$16.32	2.86

Summary

Rigel Pharmaceuticals beats Protalix BioTherapeutics on 14 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Climb Bio?

Protalix BioTherapeutics (NYSE:PLX) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 5 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for Climb Bio and 2 mentions for Protalix BioTherapeutics. Climb Bio's average media sentiment score of 0.68 beat Protalix BioTherapeutics' score of 0.24 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Climb Bio has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Climb Bio	N/A	-31.79%	-30.79%

Protalix BioTherapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.69	$8.31M	$0.23	11.70
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Protalix BioTherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 346.10%. Climb Bio has a consensus target price of $26.92, indicating a potential upside of 91.62%. Given Protalix BioTherapeutics' higher possible upside, equities research analysts plainly believe Protalix BioTherapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Climb Bio beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$216.74M	$3.89B	$7.24B	$23.10B
Dividend Yield	N/A	3.64%	2.57%	3.62%
P/E Ratio	-20.69	14.23	275.49	28.21
Price / Sales	2.69	1,423.41	639.54	20.30
Price / Cash	17.80	108.90	76.25	36.36
Price / Book	5.72	15.45	10.46	4.67
Net Income	$8.31M	-$22.86M	$3.49B	$1.07B
7 Day Performance	1.89%	-1.21%	0.59%	-1.64%
1 Month Performance	13.03%	-3.29%	-1.74%	-3.60%
1 Year Performance	42.33%	37.74%	18.13%	8.41%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	2.9448 of 5 stars	$2.69 -0.4%	$12.00 +346.1%	+42.3%	$216.74M	$80.62M	N/A	226
OLMA Olema Pharmaceuticals	2.619 of 5 stars	$9.78 -5.0%	$40.60 +315.1%	+20.2%	$855.73M	N/A	N/A	150	Positive News
CADL Candel Therapeutics	3.2883 of 5 stars	$11.12 +4.1%	$19.29 +73.4%	+125.3%	$850.89M	N/A	N/A	55
GERN Geron	1.3742 of 5 stars	$1.31 -4.4%	$4.00 +205.3%	-1.5%	$841.64M	$183.88M	N/A	258
RIGL Rigel Pharmaceuticals	4.5337 of 5 stars	$44.36 -2.2%	$59.00 +33.0%	+34.3%	$820.75M	$276.79M	2.72	174

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. OLMA, CADL, GERN, RIGL, and CLYM

How does Protalix BioTherapeutics compare to Olema Pharmaceuticals?

Summary

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Geron?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Summary

How does Protalix BioTherapeutics compare to Climb Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. OLMA, CADL, GERN, RIGL, and CLYM

How does Protalix BioTherapeutics compare to Olema Pharmaceuticals?

Which has more risk and volatility, PLX or OLMA?

Do insiders & institutionals believe in PLX or OLMA?

Which has preferable earnings & valuation, PLX or OLMA?

Does the media favor PLX or OLMA?

Do analysts prefer PLX or OLMA?

Is PLX or OLMA more profitable?

Summary

How does Protalix BioTherapeutics compare to Candel Therapeutics?

Does the media refer more to PLX or CADL?

Do analysts prefer PLX or CADL?

Is PLX or CADL more profitable?

Do insiders and institutionals hold more shares of PLX or CADL?

Which has higher earnings & valuation, PLX or CADL?

Which has more risk & volatility, PLX or CADL?

Summary

How does Protalix BioTherapeutics compare to Geron?

Which has more risk and volatility, GERN or PLX?

Do institutionals and insiders believe in GERN or PLX?

Which has higher valuation and earnings, GERN or PLX?

Do analysts prefer GERN or PLX?

Does the media favor GERN or PLX?

Is GERN or PLX more profitable?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Do institutionals & insiders hold more shares of PLX or RIGL?

Does the media prefer PLX or RIGL?

Which has more risk & volatility, PLX or RIGL?

Is PLX or RIGL more profitable?

Do analysts rate PLX or RIGL?

Which has higher earnings & valuation, PLX or RIGL?

Summary

How does Protalix BioTherapeutics compare to Climb Bio?

Do institutionals and insiders believe in PLX or CLYM?

Does the media prefer PLX or CLYM?

Which has more risk & volatility, PLX or CLYM?

Is PLX or CLYM more profitable?

Which has preferable valuation & earnings, PLX or CLYM?

Do analysts recommend PLX or CLYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools